Literature DB >> 23230076

Peripheral gangrene in children with atypical hemolytic uremic syndrome.

Michal Malina1, Ashima Gulati, Arvind Bagga, Mohammad A Majid, Eva Simkova, Franz Schaefer.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy with severe clinical manifestation, frequent recurrence, and poor long-term prognosis. It is usually caused by abnormalities in complement regulation. We report 2 cases of children affected by a catastrophic extrarenal complication. A 4-year-old Indian girl developed gangrene of the finger tips 2 days after initial presentation of aHUS. Factor H autoantibodies were identified. Renal function continued to decline despite daily plasma exchanges, and she was started on peritoneal dialysis 5 days after admission. The distal tips of the left hand remained gangrenous with a line of demarcation. Three weeks later, she did not return for follow-up and died at home because of dialysis-related complications. An Arabic girl developed end-stage renal disease due to aHUS in the fourth month after birth. A de novo activating C3 mutation was found. At age 9 months, she suddenly developed ischemic changes in fingers of both hands and several toes. The lesions progressed, and several finger tips became gangrenous despite intense plasma exchange therapy. The decision was made to administer complement blocking therapy with the C5 antibody eculizumab. All nonnecrotic digits rapidly regained perfusion. The 3 already gangrenous fingers healed with loss of the end phalanges. During maintenance, eculizumab aHUS activity subsided completely and some late recovery of renal function was observed. aHUS may present by thrombotic macroangiopathy of small peripheral arteries. Eculizumab appears effective in preserving tissue viability if administered before gangrene occurs and should be considered as first-line rescue therapy in such cases.

Entities:  

Mesh:

Year:  2012        PMID: 23230076     DOI: 10.1542/peds.2012-0903

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  23 in total

Review 1.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

2.  Macrovascular involvement in a child with atypical hemolytic uremic syndrome.

Authors:  Karolis Ažukaitis; Chantal Loirat; Michal Malina; Irina Adomaitienė; Augustina Jankauskienė
Journal:  Pediatr Nephrol       Date:  2013-12-19       Impact factor: 3.714

Review 3.  Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.

Authors:  Samuel Deshayes; Nicolas Martin Silva; Valérie Chatelet; Sylvain Chantepie; Moglie Le Quintrec; François Comoz; Frank Bridoux; Marie-Agnès Dragon-Durey; Achille Aouba
Journal:  Clin Rheumatol       Date:  2018-03-07       Impact factor: 2.980

Review 4.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

5.  Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.

Authors:  Cynthia M Magro; Shabnam Momtahen; Joseph Justin Mulvey; Aminah H Yassin; Robert B Kaplan; Jeffrey C Laurence
Journal:  Am J Dermatopathol       Date:  2015-05       Impact factor: 1.533

6.  Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.

Authors:  Rodney D Gilbert; Darren J Fowler; Elizabeth Angus; Stephen A Hardy; Louise Stanley; Timothy H Goodship
Journal:  Pediatr Nephrol       Date:  2013-04-28       Impact factor: 3.714

7.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

Review 8.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

9.  Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.

Authors:  Khadizha Emirova; Elena Volokhina; Evgenia Tolstova; Bert van den Heuvel
Journal:  BMJ Case Rep       Date:  2016-02-15

10.  Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.

Authors:  Kibriya Fidan; Nilüfer Göknar; Bora Gülhan; Engin Melek; Zeynep Y Yıldırım; Esra Baskın; Mutlu Hayran; Kaan Gülleroglu; Zeynep B Özçakar; Fatih Ozaltin; Oguz Soylemezoglu
Journal:  Pediatr Nephrol       Date:  2018-04-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.